Fasudil__ROCK inhibitor STING agonist-1
Product Name
Fasudil
Description
ROCK inhibitor
Purity
>98% (TLC); NMR (Conforms)
CAS No.
103745-39-7
Molecular Formula
C14H17N3O2S•HCl
Molecular Weight
327.83
Storage Temperature
-20ºC
Shipping Temperature
Shipped Ambient
Product Type
Inhibitor
Solubility
May be dissolved in DMSO (75 mg/ml) or water (100 mg/ml)
Source
Synthetic
Appearance
Powder
SMILES
C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CN=C3
InChI
InChI=1S/C14H17N3O2S/c18-20(19,17-9-2-6-15-8-10-17)14-4-1-3-12-11-16-7-5-13(12)14/h1,3-5,7,11,15H,2,6,8-10H2
InChIKey
NGOGFTYYXHNFQH-UHFFFAOYSA-N
Safety Phrases
Classification: Caution: Substance not yet fully tested.
Safety Phrases:
S22 – Do not breathe dust.
S24/25 – Avoid contact with skin and eyes
S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection
Cite This Product
Fasudil (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-371)
References PubMed ID::http://www.ncbi.nlm.nih.gov/pubmed/19124014
Alternative Names
1-(5-Isoquinolinylsulfonyl) homopiperazine hydrochloride; 5-(1,4-Diazepan-1-ylsulfonyl)isoquinoline
Research Areas
Cell Signaling, Neuroscience
PubChem ID
3547
Scientific Background
Fasudil is a ROCK2 inhibitor with some action on PRK2 and MSK1 (IC50 values are 1.9 µM, 4 µM and 5 µM respectively). It is also shown to inhibit RSK1, RSK2, PKA, AMPK and PKd1. It is also a calcium channel antagonist and vasodilator.
References
1. Shirotani M., et al. (1991) J. Pharmacol. Exp. Ther. 259(2): 738-744.
2. Arai M., Nozawa R., et al. (1993) Biochem. Pharmacol. 46(8): 1487-1490.
3. Satoh S., et al. (1996) Br. J. Pharmacol. 118(7): 1592-1606.
4. Sward K., et al. (2000) J. Physiol. 522: 33-49.
ROCK inhibitor
Safety Phrases:
S22 – Do not breathe dust.
S24/25 – Avoid contact with skin and eyes
S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection
2. Arai M., Nozawa R., et al. (1993) Biochem. Pharmacol. 46(8): 1487-1490.
3. Satoh S., et al. (1996) Br. J. Pharmacol. 118(7): 1592-1606.
4. Sward K., et al. (2000) J. Physiol. 522: 33-49.